{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T18:05:47Z","timestamp":1770919547630,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103357","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T22:27:32Z","timestamp":1635719252000},"page":"103357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes"],"prefix":"10.1016","volume":"57","author":[{"given":"Alessandro","family":"Dinoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Pasquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Bratina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Manganotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103357_bib0001","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103357_bib0002","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103357_bib0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103357_bib0004","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2020.1763304","article-title":"An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis","volume":"21","author":"Valencia-Sanchez","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2021.103357_bib0005","first-page":"1","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients","author":"Jordan","year":"2020","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103357_bib0006","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count pro fi les in dimethyl fumarate \u2013 treated patients with MS","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2021.103357_bib0007","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103357_bib0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2019.01.007","article-title":"Factors associated with dimethyl fumarate-induced lymphopenia","volume":"398","author":"Sainz de la Maza","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103357_bib0009","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","article-title":"Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population","volume":"267","author":"Sabin","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103357_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102781","article-title":"Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment","volume":"49","author":"Garbo","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103357_bib0011","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing\u2013remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103357_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000397","article-title":"Patient outcomes influenced by reduced lymphocyte counts after dimethyl fumarate initiation","volume":"4","author":"Wright","year":"2017","journal-title":"Neurol Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2021.103357_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.01343","article-title":"Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort","volume":"10","author":"Manni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103357_bib0014","first-page":"1","article-title":"Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population","author":"Boffa","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103357_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2017.12.016","article-title":"The evolution of \u201cno evidence of disease activity\u201d in multiple sclerosis","volume":"20","author":"Lu","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103357_bib0016","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: an italian, multicenter, real-world study","volume":"32","author":"Mirabella","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103357_bib0017","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00415-016-8175-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study","volume":"263","author":"Miclea","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103357_bib0018","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1352458517709956","article-title":"Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center","volume":"24","author":"Smoot","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103357_bib0019","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103357_bib0020","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.msard.2018.09.009","article-title":"Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient","volume":"26","author":"Perini","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103357_bib0021","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ane.12882","article-title":"Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation","volume":"137","author":"Zecca","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2021.103357_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419843450","article-title":"Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age","volume":"12","author":"Briner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103357_bib0023","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1212\/CPJ.0000000000000800","article-title":"Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS","volume":"10","author":"Chan","year":"2020","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2021.103357_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10412-0","article-title":"Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis","author":"Lucchini","year":"2021","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821006246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:35:31Z","timestamp":1735576531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"alternative-id":["S2211034821006246"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103357","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103357"}}